Pharmaceutical Preparations · DE · CIK 1001316
Develops and commercializes novel treatments for B-cell diseases, including approved multiple sclerosis therapy BRIUMVI
Comparable business profile · signals at a glance
In the 90 days to Nov 24, 2025: 1 sold $163K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 24, 2025 | Echelard YannDirector | Sell | 5,000 | $32.57 | $163K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 4 reputable articles.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗